Articles related to RESEARCH & CLINICAL TRIALS

Chemotherapy-free regimens for Ph+ ALL have shown complete response rates of 94-100% with minimal toxicity, potentially eliminating the need for stem cell transplant in many patients.

A new network meta-analysis reveals that high-dose psilocybin may be as effective as escitalopram for treating depressive symptoms, with a standardized mean difference of 0.31 compared to placebo in antidepressant trials.

Recent studies suggest that ALS may begin to develop shortly after conception, taking years or decades before symptoms appear, highlighting the importance of early intervention and lifestyle modifications.

Osimertinib significantly improved progression-free survival in patients with unresectable stage III EGFR-mutant NSCLC after chemoradiotherapy, with a hazard ratio of 0.16 compared to placebo.

Actigraphy devices revealed significant improvements in sleep patterns with nighttime levodopa use, despite patients not perceiving these changes subjectively.

Recent studies have identified a range of chemical compounds released by face masks, including microplastics, volatile organic compounds, and plasticizers, prompting a closer examination of potential cumulative exposure risks.